<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1d3 20150301//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 39.96?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="iso-abbrev">PLoS ONE</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group><journal-title>PLoS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, CA USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">5967746</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0197504</article-id><article-id pub-id-type="publisher-id">PONE-D-17-42117</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Organisms</subject><subj-group><subject>Viruses</subject><subj-group><subject>RNA viruses</subject><subj-group><subject>Orthomyxoviruses</subject><subj-group><subject>Influenza Viruses</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Microbiology</subject><subj-group><subject>Medical Microbiology</subject><subj-group><subject>Microbial Pathogens</subject><subj-group><subject>Viral Pathogens</subject><subj-group><subject>Orthomyxoviruses</subject><subj-group><subject>Influenza Viruses</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Pathology and Laboratory Medicine</subject><subj-group><subject>Pathogens</subject><subj-group><subject>Microbial Pathogens</subject><subj-group><subject>Viral Pathogens</subject><subj-group><subject>Orthomyxoviruses</subject><subj-group><subject>Influenza Viruses</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Organisms</subject><subj-group><subject>Viruses</subject><subj-group><subject>Viral Pathogens</subject><subj-group><subject>Orthomyxoviruses</subject><subj-group><subject>Influenza Viruses</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Infectious Diseases</subject><subj-group><subject>Viral Diseases</subject><subj-group><subject>Influenza</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immunity</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immunity</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>People and places</subject><subj-group><subject>Geographical locations</subject><subj-group><subject>Asia</subject><subj-group><subject>Hong Kong</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Vaccination and Immunization</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Vaccination and Immunization</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Public and Occupational Health</subject><subj-group><subject>Preventive Medicine</subject><subj-group><subject>Vaccination and Immunization</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Pathology and Laboratory Medicine</subject><subj-group><subject>Serology</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Physiology</subject><subj-group><subject>Immune Physiology</subject><subj-group><subject>Antibodies</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Physiology</subject><subj-group><subject>Immune Physiology</subject><subj-group><subject>Antibodies</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immune System Proteins</subject><subj-group><subject>Antibodies</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immune System Proteins</subject><subj-group><subject>Antibodies</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Biochemistry</subject><subj-group><subject>Proteins</subject><subj-group><subject>Immune System Proteins</subject><subj-group><subject>Antibodies</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>People and Places</subject><subj-group><subject>Population Groupings</subject><subj-group><subject>Age Groups</subject></subj-group></subj-group></subj-group></article-categories><title-group><article-title>Incidence of influenza A(H3N2) virus infections in Hong Kong in a longitudinal sero-epidemiological study, 2009-2015</article-title><alt-title alt-title-type="running-head">Serologic study of influenza A(H3N2)</alt-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Wei</surname><given-names>Vivian W. I.</given-names></name><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Formal analysis</role><role content-type="http://credit.casrai.org/">Project administration</role><role content-type="http://credit.casrai.org/">Writing &#x02013; original draft</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="aff" rid="aff002"><sup>2</sup></xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Wong</surname><given-names>Jessica Y. T.</given-names></name><role content-type="http://credit.casrai.org/">Formal analysis</role><role content-type="http://credit.casrai.org/">Writing &#x02013; original draft</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Perera</surname><given-names>Ranawaka A. P. M.</given-names></name><role content-type="http://credit.casrai.org/">Methodology</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="aff" rid="aff003"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Kwok</surname><given-names>Kin On</given-names></name><role content-type="http://credit.casrai.org/">Project administration</role><role content-type="http://credit.casrai.org/">Supervision</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff002"><sup>2</sup></xref><xref ref-type="aff" rid="aff004"><sup>4</sup></xref><xref ref-type="aff" rid="aff005"><sup>5</sup></xref></contrib><contrib contrib-type="author"><name><surname>Fang</surname><given-names>Vicky J.</given-names></name><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Barr</surname><given-names>Ian G.</given-names></name><role content-type="http://credit.casrai.org/">Resources</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff006"><sup>6</sup></xref><xref ref-type="aff" rid="aff007"><sup>7</sup></xref></contrib><contrib contrib-type="author"><name><surname>Peiris</surname><given-names>J. S. Malik</given-names></name><role content-type="http://credit.casrai.org/">Methodology</role><role content-type="http://credit.casrai.org/">Resources</role><role content-type="http://credit.casrai.org/">Supervision</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="aff" rid="aff003"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Riley</surname><given-names>Steven</given-names></name><role content-type="http://credit.casrai.org/">Conceptualization</role><role content-type="http://credit.casrai.org/">Funding acquisition</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff008"><sup>8</sup></xref></contrib><contrib contrib-type="author"><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-6297-7154</contrib-id><name><surname>Cowling</surname><given-names>Benjamin J.</given-names></name><role content-type="http://credit.casrai.org/">Conceptualization</role><role content-type="http://credit.casrai.org/">Funding acquisition</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="corresp" rid="cor001">*</xref></contrib></contrib-group><aff id="aff001"><label>1</label>
<addr-line>WHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, Hong Kong Special Administrative Region, China</addr-line></aff><aff id="aff002"><label>2</label>
<addr-line>Jockey Club School of Public Health and Primary Care, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, Hong Kong Special Administrative Region, China</addr-line></aff><aff id="aff003"><label>3</label>
<addr-line>Centre of Influenza Research, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, Hong Kong Special Administrative Region, China</addr-line></aff><aff id="aff004"><label>4</label>
<addr-line>Stanley Ho Centre for Emerging Infectious Diseases, The Chinese University of Hong Kong, Shatin, Hong Kong, Hong Kong Special Administrative Region, China</addr-line></aff><aff id="aff005"><label>5</label>
<addr-line>Shenzhen Research Institute of the Chinese University of Hong Kong, Shenzhen, China</addr-line></aff><aff id="aff006"><label>6</label>
<addr-line>WHO Collaborating Centre for Reference and Research, Melbourne, Victoria, Australia</addr-line></aff><aff id="aff007"><label>7</label>
<addr-line>Department of Microbiology and Immunology, University of Melbourne, Melbourne, Victoria, Australia</addr-line></aff><aff id="aff008"><label>8</label>
<addr-line>MRC Centre for Outbreak Analysis and Modelling, Department for Infectious Disease Epidemiology, Imperial College London, London, United Kingdom</addr-line></aff><contrib-group><contrib contrib-type="editor"><name><surname>Nishiura</surname><given-names>Hiroshi</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1"><addr-line>Hokkaido University Graduate School of Medicine, JAPAN</addr-line></aff><author-notes><fn fn-type="COI-statement" id="coi001"><p><bold>Competing Interests: </bold>I have read the journal's policy and the authors of this manuscript have the following competing interests: BJC has received research funding from Sanofi Pasteur for a study of influenza vaccine effectiveness. BJC is a Section Editor of PLoS ONE. This does not alter the authors&#x02019; adherence to all the PLOS ONE policies on sharing data and materials. The authors report no other potential conflicts of interest.</p></fn><corresp id="cor001">* E-mail: <email>bcowling@hku.hk</email></corresp></author-notes><pub-date pub-type="epub"><day>24</day><month>5</month><year>2018</year></pub-date><pub-date pub-type="collection"><year>2018</year></pub-date><volume>13</volume><issue>5</issue><elocation-id>e0197504</elocation-id><history><date date-type="received"><day>30</day><month>11</month><year>2017</year></date><date date-type="accepted"><day>3</day><month>5</month><year>2018</year></date></history><permissions><copyright-statement>&#x000a9; 2018 Wei et al</copyright-statement><copyright-year>2018</copyright-year><copyright-holder>Wei et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="pone.0197504.pdf"/><abstract><sec id="sec001"><title>Background</title><p>Many serologic studies were done during and after the 2009 influenza pandemic, to estimate the cumulative incidence of influenza A(H1N1)pdm09 virus infections, but there are few comparative estimates of the incidence of influenza A(H3N2) virus infections during epidemics.</p></sec><sec id="sec002"><title>Methods</title><p>We conducted a longitudinal serologic study in Hong Kong. We collected sera annually and tested samples from 2009&#x02013;13 by HAI against the A/Perth/16/2009(H3N2) virus, and samples from 2013&#x02013;15 against the A/Victoria/361/2011(H3N2) virus using the hemagglutination inhibition (HAI) assay. We estimated the cumulative incidence of infections based on 4-fold or greater rises in HAI titers in consecutive sera.</p></sec><sec id="sec003"><title>Results</title><p>There were four major H3N2 epidemics: (1) Aug-Oct 2010; (2) Mar-Jun 2012; (3) Jul-Oct 2013; and (4) Jun-Jul 2014. Between 516 and 619 relevant pairs of sera were available for each epidemic. We estimated that 9%, 19%, 7% and 7% of the population were infected in each epidemic, respectively, with higher incidence in children in epidemics 1 and 4.</p></sec><sec id="sec004"><title>Conclusions</title><p>We found that re-infections in each of the four H3N2 epidemics that occurred from 2010 through 2014 were rare. The largest H3N2 epidemic occurred with the lowest level of pre-epidemic immunity.</p></sec></abstract><funding-group><award-group id="award001"><funding-source><institution-wrap><institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/501100005847</institution-id><institution>Health and Medical Research Fund</institution></institution-wrap></funding-source><award-id>13120732</award-id><principal-award-recipient><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-6297-7154</contrib-id><name><surname>Cowling</surname><given-names>Benjamin J.</given-names></name></principal-award-recipient></award-group><award-group id="award002"><funding-source><institution>Research Fund for the Control of Infectious Diseases</institution></funding-source><award-id>PHE-21</award-id><principal-award-recipient><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-6297-7154</contrib-id><name><surname>Cowling</surname><given-names>Benjamin J.</given-names></name></principal-award-recipient></award-group><award-group id="award003"><funding-source><institution>Area of Excellence Scheme of the University Grants Committee of Hong Kong</institution></funding-source><award-id>AoE/M-12/06</award-id><principal-award-recipient><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-6297-7154</contrib-id><name><surname>Cowling</surname><given-names>Benjamin J.</given-names></name></principal-award-recipient></award-group><award-group id="award004"><funding-source><institution>Medical Research Council</institution></funding-source><award-id>Project MR/J008761/1</award-id><principal-award-recipient><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-6297-7154</contrib-id><name><surname>Cowling</surname><given-names>Benjamin J.</given-names></name></principal-award-recipient></award-group><award-group id="award005"><funding-source><institution-wrap><institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/100004440</institution-id><institution>Wellcome Trust</institution></institution-wrap></funding-source><award-id>Project 093488/Z/10/Z Investigator Award 200861/Z/16/Z</award-id><principal-award-recipient><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-6297-7154</contrib-id><name><surname>Cowling</surname><given-names>Benjamin J.</given-names></name></principal-award-recipient></award-group><award-group id="award006"><funding-source><institution>National Institute for General Medical Sciences</institution></funding-source><award-id>MIDAS U01 GM110721-01</award-id><principal-award-recipient><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-6297-7154</contrib-id><name><surname>Cowling</surname><given-names>Benjamin J.</given-names></name></principal-award-recipient></award-group><award-group id="award007"><funding-source><institution-wrap><institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/501100000272</institution-id><institution>National Institute for Health Research</institution></institution-wrap></funding-source><award-id>Health Protection Research Unit funding</award-id><principal-award-recipient><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-6297-7154</contrib-id><name><surname>Cowling</surname><given-names>Benjamin J.</given-names></name></principal-award-recipient></award-group><funding-statement>This project was supported by the Health and Medical Research Fund, Hong Kong (grant no. 13120732), the Research Grants Council, Hong Kong (grant no. 776810), the Research Fund for the Control of Infectious Diseases, Hong Kong (grant no: PHE-21), the Area of Excellence Scheme of the University Grants Committee of Hong Kong (grant no. AoE/M-12/06), and the Research Grants Council of the Hong Kong Special Administrative Region, China (project No. T11-705/14N). SR acknowledges support from Wellcome Trust (200861/Z/16/Z); Medical Research Council, UK (Project MR/J008761/1); National Institute for Health Research (UK, for Health Protection Research Unit funding); the National Institute of General Medical Sciences (MIDAS U01 GM110721-01). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement></funding-group><counts><fig-count count="4"/><table-count count="2"/><page-count count="11"/></counts><custom-meta-group><custom-meta id="data-availability"><meta-name>Data Availability</meta-name><meta-value>Raw data are available via Dryad at: doi:<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.5061/dryad.7c93n5s">10.5061/dryad.7c93n5s</ext-link>.</meta-value></custom-meta></custom-meta-group></article-meta><notes><title>Data Availability</title><p>Raw data are available via Dryad at: doi:<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.5061/dryad.7c93n5s">10.5061/dryad.7c93n5s</ext-link>.</p></notes></front><body><sec sec-type="intro" id="sec005"><title>Introduction</title><p>Influenza virus infections account for a significant annual disease burden [<xref rid="pone.0197504.ref001" ref-type="bibr">1</xref>, <xref rid="pone.0197504.ref002" ref-type="bibr">2</xref>]. On average, influenza A(H3N2) epidemics tend to have the greatest impact on morbidity and mortality [<xref rid="pone.0197504.ref003" ref-type="bibr">3</xref>&#x02013;<xref rid="pone.0197504.ref005" ref-type="bibr">5</xref>], particularly in elderly individuals [<xref rid="pone.0197504.ref006" ref-type="bibr">6</xref>, <xref rid="pone.0197504.ref007" ref-type="bibr">7</xref>]. Influenza A(H3N2) viruses have also evolved more rapidly in more recent years, and between January 2000 and January 2015 there were 9 changes in the recommended A(H3N2) component of influenza vaccines compared to 4 changes in the A(H1N1) component including the A(H1N1)pdm09 pandemic virus [<xref rid="pone.0197504.ref008" ref-type="bibr">8</xref>]. Many serologic studies were done during and after the 2009 influenza pandemic, to estimate the cumulative incidence of influenza A(H1N1)pdm09 virus infections in the first [<xref rid="pone.0197504.ref009" ref-type="bibr">9</xref>, <xref rid="pone.0197504.ref010" ref-type="bibr">10</xref>] and subsequent waves [<xref rid="pone.0197504.ref005" ref-type="bibr">5</xref>, <xref rid="pone.0197504.ref011" ref-type="bibr">11</xref>], and the development of population immunity [<xref rid="pone.0197504.ref012" ref-type="bibr">12</xref>]. In comparison, there are relatively few population-based estimates of influenza A(H3N2) virus infections [<xref rid="pone.0197504.ref005" ref-type="bibr">5</xref>, <xref rid="pone.0197504.ref013" ref-type="bibr">13</xref>]. Nor are there studies describing the role of population immunity in shaping consecutive epidemics of influenza A(H3N2).</p><p>In 2009 we began a population-based sero-epidemiologic study of influenza A(H1N1)pdm09 [<xref rid="pone.0197504.ref014" ref-type="bibr">14</xref>]. In that study we enrolled people from the general community using a systematic approach, and collected sera before and after the first wave of influenza A(H1N1)pdm09 virus infections. We subsequently extended this study through to 2015, collecting sera approximately once per year, and replacing participants that dropped out to maintain a sample size of between 800 and 1200 persons in each round of blood draws. In each study round, participants from previous rounds were invited to continue participating in the study. Participants that dropped out were replaced by new participants recruited via the same recruitment approach, i.e. random digit dialing. We used the hemagglutination inhibition (HAI) assay to measure antibody titers against circulating viruses. We have reported data from the first 4 rounds of blood draws, that covered two epidemics of A(H1N1)pdm09 and one epidemic of A(H3N2) [<xref rid="pone.0197504.ref005" ref-type="bibr">5</xref>]. Here we report data on influenza A(H3N2) virus infections in 4 consecutive epidemics in 2010, 2012, 2013 and 2014. The objective of this study is to describe the overall and age-specific incidence of H3N2 infections in Hong Kong, and to examine patterns in individual and population immunity as represented by HAI titers.</p></sec><sec sec-type="materials|methods" id="sec006"><title>Methods</title><sec id="sec007"><title>Study design</title><p>We designed a community-based open cohort study, with regular rounds of blood draws from cohort members, and regular replacement of participants that dropped out to maintain the sample size. The recruitment was on a household basis. At the start of the study in 2009, we used random digit dialing to approach people to participate in this study. People would be eligible to participate if they were at least 2 years of age and normally slept in the approached household for at least 5 nights per week. People who agreed to participate were invited to the study clinic where we collected baseline information on socio-demographics, any underlying medical conditions, and vaccination history, along with a 5ml clotted blood sample. The first round of blood draws was collected between July and September 2009 [<xref rid="pone.0197504.ref014" ref-type="bibr">14</xref>]. From November 2009 to February 2010 we invited participants to return to the study clinic for the second round of blood draws. We continued the study, with blood collected approximately one year apart, for 5 additional years around the start of each calendar year from 2011 to 2015. Therefore, our study comprised a total of seven rounds of blood draws (Rounds 1&#x02013;7). In each round, in addition to blood samples, we administered the baseline questionnaire to new participants, and a brief questionnaire to continuing participants. Participants were compensated with HK$100 (around US$13) in the form of cash voucher and, since Round 3, HK$20 (around US$2.5) cash.</p></sec><sec id="sec008"><title>Ethical approval</title><p>The study protocol was approved by the Institutional Review Board of the University of Hong Kong. We obtained written consent from participants 18 years of age or older. For participants aged 2 to 7 years, proxy written consent from parents or legal guardians was obtained. For participants aged 8 to 17 years, proxy written consent from parents or legal guardians was obtained in addition to their own written assent.</p></sec><sec id="sec009"><title>Laboratory methods</title><p>We used the HAI assay to quantify the antibody titers against prevalent influenza A(H3N2) strains in the serum samples. Antibody titers were determined by testing serial 2-fold dilutions from 1:10 to 1:10240 in duplicate. The reciprocal of the highest dilution of serum that prevents complete hemagglutination in both duplicate wells was regarded as the antibody titer. We tested sera from Rounds 2&#x02013;5 against the A/Perth/16/2009 (H3N2) virus, and those from Rounds 5&#x02013;7 against the A/Victoria/361/2011 (H3N2) virus. We tested paired specimens from the same participants from consecutive rounds in parallel to ensure valid inferences of infections via rises in consecutive HAI titers.</p></sec><sec id="sec010"><title>Statistical analysis</title><p>The primary outcome was serologic evidence of influenza A(H3N2) virus infection, which is defined as a four-fold or greater rise in HAI titers between consecutive paired sera. We identified major H3N2 epidemics from 2010 to 2015 using the weekly proportion of outpatient consultations with influenza-like illness multiplied by the weekly type/subtype-specific laboratory detection rates in the Public Health Laboratory Services Branch of the Centre for Health Protection [<xref rid="pone.0197504.ref006" ref-type="bibr">6</xref>, <xref rid="pone.0197504.ref015" ref-type="bibr">15</xref>], defining the major H3N2 epidemics as those in which the proportion of samples positive for A(H3N2) exceeded 5% of all specimens submitted for at least 6 consecutive weeks. We estimated the cumulative incidence for each epidemic in four age groups (2-19y, 20-44y, 45-64y and &#x02265;65y). Confidence intervals (CI) for the age-specific estimates were estimated by the exact binomial method; whereas those for the overall age group were estimated via the normal approximation and then age-standardized to the Hong Kong population in 2010. We excluded all participants with self-reported and unreported vaccination status in all analyses.</p><p>We estimated the rate of waning in HAI titers (in the absence of vaccination) against each virus strain by fitting log-linear regression models to HAI titers since infection in infected persons, in whom we had previously identified a &#x02265;4 fold rise in HAI titers between paired sera and the titer value of the latter specimens being &#x02265;20. We explored the waning rate since the time of infection, assuming that infections occurred in the peak of each community epidemic to determine the time since infection of the subsequent blood draws. We used logistic regression models to estimate the correlation of pre-epidemic HAI titers with protection against infection, where the reduction in the odds of infection risk at each HAI titer was estimated relative to an HAI titer &#x0003c;10. Having established the protection against serologic evidence of influenza virus infection, we used these risks to estimate the susceptibility index for each age group of participant (1 minus mean of reduction in the infection odds) at each HAI titer. The index for each epidemic was calculated as the average of the index values of all participants sampled before the corresponding epidemic, standardized to the population age structure, and ranged from 0 (i.e. population fully protected) to 1 (i.e. population fully susceptible to influenza virus infection). All statistical analyses were conducted using R version 3.3.2 (R Foundation for Statistical Computing, Vienna, Austria).</p></sec></sec><sec sec-type="results" id="sec011"><title>Results</title><p>The timeline of our study is shown in <xref ref-type="fig" rid="pone.0197504.g001">Fig 1</xref>, including the periods of the 7 rounds of sera collection, along with local surveillance data on influenza epidemics. During the study period, there were four major H3N2 epidemics and each was neatly bracketed by rounds of sera collection: (1) August-October 2010 (bracketed by Rounds 2 and 3); (2) March-June 2012 (bracketed by Rounds 4 and 5); (3) July-October 2013 (bracketed by Rounds 5 and 6); and (4) June-July 2014 (bracketed by Rounds 6 and 7). The four epidemics are indicated in <xref ref-type="fig" rid="pone.0197504.g001">Fig 1</xref>. The first two epidemics were dominated by A/Perth/16/2009-like viruses [<xref rid="pone.0197504.ref016" ref-type="bibr">16</xref>], while A/Victoria/361/2011-like viruses were predominant in the third and fourth epidemics.</p><fig id="pone.0197504.g001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0197504.g001</object-id><label>Fig 1</label><caption><title>Timeline of our study rounds and community influenza virus activity.</title><p>In total we collected blood in seven rounds, with each of the four numbered H3N2 epidemics being neatly bracketed by two consecutive rounds of blood draws. The y-axis shows weekly influenza virus activity in Hong Kong from 2009 to 2014, measured for each influenza type/subtype as the weekly proportion of outpatient consultations associated with influenza-like-illness in sentinel outpatient clinics multiplied by the weekly proportions of laboratory specimens testing positive for influenza A(H3N2), A(H1N1)pdm09 and B viruses respectively. For each type/subtype the activity level should correlate with incidence of infections within an epidemic, but changes in consultation behaviors between epidemics (e.g. in 2009/10) may also influence observed &#x02018;activity&#x02019; levels.</p></caption><graphic xlink:href="pone.0197504.g001"/></fig><p>For each of the four epidemics, we selected participants who provided sera in the rounds bracketing the corresponding epidemic, and inferred the cumulative incidence of infections in that epidemic based on analyses of the relevant pairs of sera. Between 516 and 619 relevant pairs of sera were available for each epidemic (<xref ref-type="table" rid="pone.0197504.t001">Table 1</xref>). Participants who self-reported receipt of vaccination before or during the corresponding influenza season were excluded from the analysis.</p><table-wrap id="pone.0197504.t001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0197504.t001</object-id><label>Table 1</label><caption><title>Characteristics of participants with paired sera available for each influenza A(H3N2) epidemic studied.</title></caption><alternatives><graphic id="pone.0197504.t001g" xlink:href="pone.0197504.t001"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">Epidemic 1</th><th align="center" rowspan="1" colspan="1">Epidemic 2</th><th align="center" rowspan="1" colspan="1">Epidemic 3</th><th align="center" rowspan="1" colspan="1">Epidemic 4</th></tr><tr><th align="left" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">(n = 516)</th><th align="center" rowspan="1" colspan="1">(n = 558)</th><th align="center" rowspan="1" colspan="1">(n = 619)</th><th align="center" rowspan="1" colspan="1">(n = 585)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><bold>Age (years)</bold></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;2&#x02013;19</td><td align="left" rowspan="1" colspan="1">516 (100%)</td><td align="left" rowspan="1" colspan="1">558 (100%)</td><td align="left" rowspan="1" colspan="1">619 (100%)</td><td align="left" rowspan="1" colspan="1">585 (100%)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;20&#x02013;44</td><td align="left" rowspan="1" colspan="1">57 (11%)</td><td align="left" rowspan="1" colspan="1">24 (4%)</td><td align="left" rowspan="1" colspan="1">32 (5%)</td><td align="left" rowspan="1" colspan="1">35 (6%)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;45&#x02013;64</td><td align="left" rowspan="1" colspan="1">133 (26%)</td><td align="left" rowspan="1" colspan="1">95 (17%)</td><td align="left" rowspan="1" colspan="1">124 (20%)</td><td align="left" rowspan="1" colspan="1">106 (18%)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x02265;65</td><td align="left" rowspan="1" colspan="1">259 (50%)</td><td align="left" rowspan="1" colspan="1">359 (64%)</td><td align="left" rowspan="1" colspan="1">330 (53%)</td><td align="left" rowspan="1" colspan="1">298 (51%)</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">67 (13%)</td><td align="left" rowspan="1" colspan="1">80 (14%)</td><td align="left" rowspan="1" colspan="1">133 (21%)</td><td align="left" rowspan="1" colspan="1">146 (25%)</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Sex</bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;Male</td><td align="left" rowspan="1" colspan="1">203 (39%)</td><td align="left" rowspan="1" colspan="1">228 (41%)</td><td align="left" rowspan="1" colspan="1">242 (39%)</td><td align="left" rowspan="1" colspan="1">229 (39%)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;Female</td><td align="left" rowspan="1" colspan="1">313 (61%)</td><td align="left" rowspan="1" colspan="1">330 (59%)</td><td align="left" rowspan="1" colspan="1">377 (61%)</td><td align="left" rowspan="1" colspan="1">356 (61%)</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Self-reported seasonal</bold><break/><bold>influenza vaccination</bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;Yes</td><td align="left" rowspan="1" colspan="1">122 (24%)</td><td align="left" rowspan="1" colspan="1">83 (15%)</td><td align="left" rowspan="1" colspan="1">139 (22%)</td><td align="left" rowspan="1" colspan="1">149 (25%)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;No</td><td align="left" rowspan="1" colspan="1">392 (76%)</td><td align="left" rowspan="1" colspan="1">466 (84%)</td><td align="left" rowspan="1" colspan="1">478 (77%)</td><td align="left" rowspan="1" colspan="1">435 (74%)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;Unknown</td><td align="left" rowspan="1" colspan="1">2 (0%)</td><td align="left" rowspan="1" colspan="1">9 (2%)</td><td align="left" rowspan="1" colspan="1">2 (0%)</td><td align="left" rowspan="1" colspan="1">1 (0%)</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Dropout</bold></td><td align="left" rowspan="1" colspan="1">302 (59%)</td><td align="left" rowspan="1" colspan="1">163 (29%)</td><td align="left" rowspan="1" colspan="1">147 (24%)</td><td align="left" rowspan="1" colspan="1">NA</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t001fn001"><p>NA = not available</p></fn></table-wrap-foot></table-wrap><p>Estimates of the cumulative incidence of A(H3N2) infections in each epidemic are shown in <xref ref-type="table" rid="pone.0197504.t002">Table 2</xref>. Overall, 7%-19% of the population were infected in each epidemic. However, epidemic 2 (Mar-Jun 2012) was substantially larger than the other epidemics with an estimated overall attack rate of 19% (95% CI: 14%, 24%). The cumulative incidence of infection was generally the highest among children, but similar across different age groups in epidemics 2 and 3. Re-infections were rare, with evidence in a small number of participants followed in particular pairs of epidemics. Of the 707 unvaccinated participants who provided samples covering epidemics 1 and 2, we identified 0 (0%) with evidence of infection in both of those epidemics i.e. re-infection. Similarly, we identified 1/706 (0.1%) for epidemics 1 and 3, 0/689 (0%) for epidemics 1 and 4, 2/639 (0.3%) for epidemics 2 and 3, 2/677 (0.3%) for epidemics 2 and 4, and 0/576 (0%) for epidemics 3 and 4.</p><table-wrap id="pone.0197504.t002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0197504.t002</object-id><label>Table 2</label><caption><title>Cumulative incidence of infection and corresponding 95% confidence intervals in each of the four influenza A(H3N2) epidemics during the study period.</title></caption><alternatives><graphic id="pone.0197504.t002g" xlink:href="pone.0197504.t002"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Age (years)</th><th align="center" rowspan="1" colspan="1">Epidemic 1 (Aug-Oct 2010)</th><th align="center" rowspan="1" colspan="1">Epidemic 2 (Mar-Jun 2012)</th><th align="center" rowspan="1" colspan="1">Epidemic 3 (Jul-Oct 2013)</th><th align="center" rowspan="1" colspan="1">Epidemic 4 (Jun-Jul 2014)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">2&#x02013;19</td><td align="left" rowspan="1" colspan="1">0.11 (0.04, 0.25)</td><td align="left" rowspan="1" colspan="1">0.21 (0.07, 0.42)</td><td align="left" rowspan="1" colspan="1">0.04 (0.00, 0.18)</td><td align="left" rowspan="1" colspan="1">0.17 (0.06, 0.36)</td></tr><tr><td align="left" rowspan="1" colspan="1">20&#x02013;44</td><td align="left" rowspan="1" colspan="1">0.05 (0.02, 0.11)</td><td align="left" rowspan="1" colspan="1">0.15 (0.08, 0.24)</td><td align="left" rowspan="1" colspan="1">0.06 (0.03, 0.13)</td><td align="left" rowspan="1" colspan="1">0.04 (0.01, 0.10)</td></tr><tr><td align="left" rowspan="1" colspan="1">45&#x02013;64</td><td align="left" rowspan="1" colspan="1">0.10 (0.06, 0.15)</td><td align="left" rowspan="1" colspan="1">0.23 (0.18, 0.28)</td><td align="left" rowspan="1" colspan="1">0.07 (0.04, 0.10)</td><td align="left" rowspan="1" colspan="1">0.04 (0.02, 0.07)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02265;65</td><td align="left" rowspan="1" colspan="1">0.17 (0.05, 0.39)</td><td align="left" rowspan="1" colspan="1">0.20 (0.09, 0.34)</td><td align="left" rowspan="1" colspan="1">0.14 (0.06, 0.26)</td><td align="left" rowspan="1" colspan="1">0.07 (0.01, 0.18)</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Overall</bold><xref ref-type="table-fn" rid="t002fn001">*</xref></td><td align="left" rowspan="1" colspan="1"><bold>0.09 (0.06, 0.13)</bold></td><td align="left" rowspan="1" colspan="1"><bold>0.19 (0.14, 0.24)</bold></td><td align="left" rowspan="1" colspan="1"><bold>0.07 (0.04, 0.10)</bold></td><td align="left" rowspan="1" colspan="1"><bold>0.07 (0.04, 0.10)</bold></td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t002fn001"><p>*Standardized by age to the Hong Kong population in 2010.</p></fn></table-wrap-foot></table-wrap><p>We estimated that 2-fold declines in HAI titers occurred after means of 175 (95% CI: 149, 211) days for A/Perth/16/2009(H3N2), and after means of 92 (95% CI: 74, 121) days for A/Victoria/361/2011(H3N2) (<xref ref-type="fig" rid="pone.0197504.g002">Fig 2</xref>). Higher HAI titers corresponded to a greater reduction in the risk of A(H3N2) infection, and an HAI titer of 40 correlated with 62% (95% CI: 55%, 68%) protection against infection (<xref ref-type="fig" rid="pone.0197504.g003">Fig 3</xref>). We were not able to stratify this analysis by strain and by epidemic due to the low number of infected cases with pre-epidemic titers &#x0003e;10.</p><fig id="pone.0197504.g002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0197504.g002</object-id><label>Fig 2</label><caption><title>Declines in HAI titers against influenza A/Perth/16/2009(H3N2) and A/Victoria/361/2011(H3N2) virus after infection.</title><p>In each panel the black regression lines indicate the rates of antibody waning from a fitted log-linear model, and the grey lines indicate the geometric mean titers at the center of each time point that sera were collected. There were 126 and 44 participants infected against A/Perth/16/2009(H3N2) and A/Victoria/361/2011(H3N2) respectively.</p></caption><graphic xlink:href="pone.0197504.g002"/></fig><fig id="pone.0197504.g003" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0197504.g003</object-id><label>Fig 3</label><caption><title>Correlation between HAI titers and protection against influenza A(H3N2) virus infection.</title><p>The upper panel shows the number of uninfected and infected persons in each pre-epidemic titer range. The lower panel shows the estimated degree of protection associated with higher pre-epidemic titers, calculated as the relative risk reduction compared with the risk at a pre-epidemic HAI titer &#x0003c;10.</p></caption><graphic xlink:href="pone.0197504.g003"/></fig><p>We estimated a susceptibility index for each epidemic based on the distribution of pre-epidemic titers and the protection curve shown in <xref ref-type="fig" rid="pone.0197504.g003">Fig 3</xref>. Compared with epidemics 1, 3 and 4, individuals were more susceptible to infection in epidemic 2 (susceptibility index = 0.88), and that epidemic had the highest overall cumulative incidence of infection of 19% (<xref ref-type="fig" rid="pone.0197504.g004">Fig 4</xref>).</p><fig id="pone.0197504.g004" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0197504.g004</object-id><label>Fig 4</label><caption><title>Comparison between susceptibility and age-standardized cumulative incidence of infection in four influenza A(H3N2) epidemics.</title><p>The susceptibility index was calculated as 1 minus relative risk reduction compared with the risk at per-epidemic HAI titer &#x0003c;10. The cumulative incidence of infection was standardized by age to the Hong Kong population in 2010. Each text 1 to 4 corresponds to epidemics 1 to 4 respectively.</p></caption><graphic xlink:href="pone.0197504.g004"/></fig></sec><sec sec-type="conclusions" id="sec012"><title>Discussion</title><p>We conducted a longitudinal serologic study over five years, allowing us to estimate the cumulative incidence of influenza A(H3N2) virus infections in four consecutive epidemics in Hong Kong. We found that 7% - 19% of the population were infected in each of these epidemics, based on the standard definition of a four-fold rise or greater in homologous titers, and the incidence of infection was generally higher in children (<xref ref-type="table" rid="pone.0197504.t002">Table 2</xref>). There was a higher cumulative incidence of infections in children (2&#x02013;19 years) and elderly individuals (65 years or greater) compared with other adults (20&#x02013;64 years) (<xref ref-type="table" rid="pone.0197504.t002">Table 2</xref>). Hong Kong is a densely populated city, where the observation here about difference in infection in age groups could be due to social mixing patterns [<xref rid="pone.0197504.ref017" ref-type="bibr">17</xref>, <xref rid="pone.0197504.ref018" ref-type="bibr">18</xref>] and transmission dynamics [<xref rid="pone.0197504.ref005" ref-type="bibr">5</xref>, <xref rid="pone.0197504.ref014" ref-type="bibr">14</xref>].</p><p>While we excluded vaccinated persons when estimating the cumulative incidence of infection, influenza vaccination coverage has been very low in Hong Kong, around 5%-10% overall, with coverage of around 40% in elderly individuals [<xref rid="pone.0197504.ref019" ref-type="bibr">19</xref>], 30% in healthcare workers [<xref rid="pone.0197504.ref020" ref-type="bibr">20</xref>], and low in most other groups including children. If we had accounted for coverage of 40% in elderly individuals with effectiveness of around 40% against H3N2 infection in these years [<xref rid="pone.0197504.ref016" ref-type="bibr">16</xref>], our estimates of the cumulative incidence of natural infection in that age group would have been 16% lower. Vaccination coverage of 5%-10% in the population as a whole, with effectiveness of 50% on average, would have had very little impact on our estimates of the overall cumulative incidence of infections.</p><p>Our estimates of the rate of antibody waning in HAI titers since infection in infected persons were similar to those in another study [<xref rid="pone.0197504.ref021" ref-type="bibr">21</xref>], where the mean time to 2-fold decline in HAI titer was 92&#x02013;175 days (<xref ref-type="fig" rid="pone.0197504.g002">Fig 2</xref>). In addition, antibody declined more quickly in participants infected with A/Victoria/361/2011-like (in epidemics 3 and 4) viruses compared with participants infected with A/Perth/16/2009-like viruses (in epidemics 1 and 2). We identified a correlation of pre-epidemic HAI titers with protection against infection. The classic study by Hobson [<xref rid="pone.0197504.ref022" ref-type="bibr">22</xref>], and other studies [<xref rid="pone.0197504.ref023" ref-type="bibr">23</xref>&#x02013;<xref rid="pone.0197504.ref025" ref-type="bibr">25</xref>], have identified a correlation of titers of 40 with 50% protection against infection, which is somewhat less than the 62% (95% CI: 55%, 68%) protection that we estimated was conferred by a pre-epidemic titer of 40 in our study. However, in contrast to most recent studies, our outcome was serologic evidence of influenza virus infection, not laboratory-confirmed influenza virus detection.</p><p>We noted that the level of population immunity varied before each of the four epidemics, and we created a single statistic to represent population immunity by combining information on titer distributions and the protection associated with those titers. Using this summary statistic of immunity, we found that the largest A(H3N2) epidemic occurred with the lowest level of pre-epidemic immunity (<xref ref-type="fig" rid="pone.0197504.g004">Fig 4</xref>). According to local surveillance data, this epidemic was dominated by A/Perth/16/2009-like viruses [<xref rid="pone.0197504.ref016" ref-type="bibr">16</xref>], which had circulated since 2009. However, despite circulation for 3 years, population immunity had declined and was lower before epidemic 2 (2012) than it was before epidemic 1 (2010) in our study (<xref ref-type="fig" rid="pone.0197504.g004">Fig 4</xref>). In further work, it would be of interest to examine alternative measures of population immunity and determine which could provide a best representation of the vulnerability of a population to a larger epidemic. For example, the level of immunity in children might be a particularly important aspect of the risk to the population as a whole for severe epidemics.</p><p>There are a number of limitations of our study. First, we used serologic data to infer the occurrence of A(H3N2) infections based on 4-fold or greater rises in HAI titers, but this approach may have missed some infections [<xref rid="pone.0197504.ref026" ref-type="bibr">26</xref>, <xref rid="pone.0197504.ref027" ref-type="bibr">27</xref>]. Some A(H3N2) infections are associated with low rises in HAI titers [<xref rid="pone.0197504.ref026" ref-type="bibr">26</xref>], and therefore we may have underestimated the cumulative incidence of infections. Second, we relied on self-reported vaccination status, and we investigated the serologic data for evidence of rises in HAI titers against A(H1N1) and A(H3N2) all together which might be indicative of vaccination rather than infection. There were no participants in epidemics 1 to 4 having such a result. These were excluded from the estimation of cumulative incidence of infections, but we may have failed to identify vaccinations in a small number of other participants. Third, our participants may not be representative of the general population because of biases in participation. We did enroll using random digit dialing to select potential participants at random from the population, but the response rate was low. Self-reported vaccination coverage in our participants was considerably higher than the general population, and we excluded vaccinated participants when estimating the cumulative incidence of infection. Fourth, the study rounds of sera did not neatly bracket each A(H3N2) epidemics and we were not able examine the two small A(H3N2) epidemics in 2011 and early 2014, or A(H3N2) infections that occurred outside the four major epidemics that we identified in <xref ref-type="fig" rid="pone.0197504.g001">Fig 1</xref>. Epidemics overlapping study rounds may underestimate or overestimate the number of infections in the epidemic following or preceding the study rounds, respectively. We are actively developing statistical techniques that can characterize these smaller epidemics with these irregular follow-up timings. Finally, we did not examine A(H1N1) or B in this study, because our focus was on A(H3N2), but cross reactive antibodies to these strains may have affected titers to A(H3N2).</p><p>In conclusion, we estimated that 7% - 19% of the Hong Kong population were infected in each of the four H3N2 epidemics from 2010 to 2014, and re-infections in these epidemics were rare. With the single measure of pre-epidemic immunity which we created, we found that the largest H3N2 epidemic occurred with the lowest level of pre-epidemic immunity.</p></sec></body><back><ack><p>The authors thank all staff and participants for their support to this study. The Melbourne WHO Collaborating Centre for Reference and Research on Influenza is supported by the Australian Government Department of Health.</p></ack><ref-list><title>References</title><ref id="pone.0197504.ref001"><label>1</label><mixed-citation publication-type="journal"><name><surname>Thompson</surname><given-names>WW</given-names></name>, <name><surname>Shay</surname><given-names>DK</given-names></name>, <name><surname>Weintraub</surname><given-names>E</given-names></name>, <name><surname>Brammer</surname><given-names>L</given-names></name>, <name><surname>Cox</surname><given-names>N</given-names></name>, <name><surname>Anderson</surname><given-names>LJ</given-names></name>, <etal>et al</etal>
<article-title>Mortality associated with influenza and respiratory syncytial virus in the United States</article-title>. <source>JAMA</source>. <year>2003</year>;<volume>289</volume>(<issue>2</issue>):<fpage>179</fpage>&#x02013;<lpage>86</lpage>. .<?supplied-pmid 12517228?><pub-id pub-id-type="pmid">12517228</pub-id></mixed-citation></ref><ref id="pone.0197504.ref002"><label>2</label><mixed-citation publication-type="journal"><name><surname>Viboud</surname><given-names>C</given-names></name>, <name><surname>Alonso</surname><given-names>WJ</given-names></name>, <name><surname>Simonsen</surname><given-names>L</given-names></name>. <article-title>Influenza in tropical regions</article-title>. <source>PLoS Med</source>. <year>2006</year>;<volume>3</volume>(<issue>4</issue>):<fpage>e89</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1371/journal.pmed.0030089">10.1371/journal.pmed.0030089</ext-link></comment> ; PubMed Central PMCID: PMCPMC1391975.<?supplied-pmid 16509764?><pub-id pub-id-type="pmid">16509764</pub-id></mixed-citation></ref><ref id="pone.0197504.ref003"><label>3</label><mixed-citation publication-type="journal"><name><surname>Frank</surname><given-names>AL</given-names></name>, <name><surname>Taber</surname><given-names>LH</given-names></name>, <name><surname>Wells</surname><given-names>JM</given-names></name>. <article-title>Comparison of infection rats and severity of illness for influenza A subtypes H1N1 and H3N2</article-title>. <source>J Infect Dis</source>. <year>1985</year>;<volume>151</volume>(<issue>1</issue>):<fpage>73</fpage>&#x02013;<lpage>80</lpage>. .<?supplied-pmid 3965595?><pub-id pub-id-type="pmid">3965595</pub-id></mixed-citation></ref><ref id="pone.0197504.ref004"><label>4</label><mixed-citation publication-type="journal"><name><surname>Wu</surname><given-names>P</given-names></name>, <name><surname>Goldstein</surname><given-names>E</given-names></name>, <name><surname>Ho</surname><given-names>LM</given-names></name>, <name><surname>Yang</surname><given-names>L</given-names></name>, <name><surname>Nishiura</surname><given-names>H</given-names></name>, <name><surname>Wu</surname><given-names>JT</given-names></name>, <etal>et al</etal>
<article-title>Excess mortality associated with influenza A and B virus in Hong Kong, 1998&#x02013;2009</article-title>. <source>J Infect Dis</source>. <year>2012</year>;<volume>206</volume>(<issue>12</issue>):<fpage>1862</fpage>&#x02013;<lpage>71</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1093/infdis/jis628">10.1093/infdis/jis628</ext-link></comment> ; PubMed Central PMCID: PMCPMC3502382.<?supplied-pmid 23045622?><pub-id pub-id-type="pmid">23045622</pub-id></mixed-citation></ref><ref id="pone.0197504.ref005"><label>5</label><mixed-citation publication-type="journal"><name><surname>Kwok</surname><given-names>KO</given-names></name>, <name><surname>Riley</surname><given-names>S</given-names></name>, <name><surname>Perera</surname><given-names>R</given-names></name>, <name><surname>Wei</surname><given-names>VWI</given-names></name>, <name><surname>Wu</surname><given-names>P</given-names></name>, <name><surname>Wei</surname><given-names>L</given-names></name>, <etal>et al</etal>
<article-title>Relative incidence and individual-level severity of seasonal influenza A H3N2 compared with 2009 pandemic H1N1</article-title>. <source>BMC Infect Dis</source>. <year>2017</year>;<volume>17</volume>(<issue>1</issue>):<fpage>337</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1186/s12879-017-2432-7">10.1186/s12879-017-2432-7</ext-link></comment> ; PubMed Central PMCID: PMCPMC5425986.<?supplied-pmid 28494805?><pub-id pub-id-type="pmid">28494805</pub-id></mixed-citation></ref><ref id="pone.0197504.ref006"><label>6</label><mixed-citation publication-type="journal"><name><surname>Wong</surname><given-names>JY</given-names></name>, <name><surname>Wu</surname><given-names>P</given-names></name>, <name><surname>Nishiura</surname><given-names>H</given-names></name>, <name><surname>Goldstein</surname><given-names>E</given-names></name>, <name><surname>Lau</surname><given-names>EH</given-names></name>, <name><surname>Yang</surname><given-names>L</given-names></name>, <etal>et al</etal>
<article-title>Infection fatality risk of the pandemic A(H1N1)2009 virus in Hong Kong</article-title>. <source>Am J Epidemiol</source>. <year>2013</year>;<volume>177</volume>(<issue>8</issue>):<fpage>834</fpage>&#x02013;<lpage>40</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1093/aje/kws314">10.1093/aje/kws314</ext-link></comment> ; PubMed Central PMCID: PMCPMC3658096.<?supplied-pmid 23459950?><pub-id pub-id-type="pmid">23459950</pub-id></mixed-citation></ref><ref id="pone.0197504.ref007"><label>7</label><mixed-citation publication-type="journal"><name><surname>Li</surname><given-names>L</given-names></name>, <name><surname>Wong</surname><given-names>JY</given-names></name>, <name><surname>Wu</surname><given-names>P</given-names></name>, <name><surname>Bond</surname><given-names>HS</given-names></name>, <name><surname>Lau</surname><given-names>EHY</given-names></name>, <name><surname>Sullivan</surname><given-names>SG</given-names></name>, <etal>et al</etal>
<article-title>Heterogeneity in Estimates of the Impact of Influenza on Population Mortality: A Systematic Review</article-title>. <source>Am J Epidemiol</source>. <year>2017</year>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1093/aje/kwx270">10.1093/aje/kwx270</ext-link></comment> .<?supplied-pmid 28679157?><pub-id pub-id-type="pmid">28679157</pub-id></mixed-citation></ref><ref id="pone.0197504.ref008"><label>8</label><mixed-citation publication-type="book"><collab>World Health Organization</collab>. <source>WHO recommendations on the composition of influenza virus vaccines World Health Organization</source>: <publisher-name>World Health Organization</publisher-name>; [<day>29</day>
<month>7</month>
<year>2017</year>]. Available from: <ext-link ext-link-type="uri" xlink:href="http://www.who.int/influenza/vaccines/virus/recommendations/en/">http://www.who.int/influenza/vaccines/virus/recommendations/en/</ext-link></mixed-citation></ref><ref id="pone.0197504.ref009"><label>9</label><mixed-citation publication-type="journal"><name><surname>Wu</surname><given-names>JT</given-names></name>, <name><surname>Ho</surname><given-names>A</given-names></name>, <name><surname>Ma</surname><given-names>ES</given-names></name>, <name><surname>Lee</surname><given-names>CK</given-names></name>, <name><surname>Chu</surname><given-names>DK</given-names></name>, <name><surname>Ho</surname><given-names>PL</given-names></name>, <etal>et al</etal>
<article-title>Estimating infection attack rates and severity in real time during an influenza pandemic: analysis of serial cross-sectional serologic surveillance data</article-title>. <source>PLoS Med</source>. <year>2011</year>;<volume>8</volume>(<issue>10</issue>):<fpage>e1001103</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1371/journal.pmed.1001103">10.1371/journal.pmed.1001103</ext-link></comment> ; PubMed Central PMCID: PMCPMC3186812.<?supplied-pmid 21990967?><pub-id pub-id-type="pmid">21990967</pub-id></mixed-citation></ref><ref id="pone.0197504.ref010"><label>10</label><mixed-citation publication-type="journal"><name><surname>Miller</surname><given-names>E</given-names></name>, <name><surname>Hoschler</surname><given-names>K</given-names></name>, <name><surname>Hardelid</surname><given-names>P</given-names></name>, <name><surname>Stanford</surname><given-names>E</given-names></name>, <name><surname>Andrews</surname><given-names>N</given-names></name>, <name><surname>Zambon</surname><given-names>M</given-names></name>. <article-title>Incidence of 2009 pandemic influenza A H1N1 infection in England: a cross-sectional serological study</article-title>. <source>Lancet</source>. <year>2010</year>;<volume>375</volume>(<issue>9720</issue>):<fpage>1100</fpage>&#x02013;<lpage>8</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/S0140-6736(09)62126-7">10.1016/S0140-6736(09)62126-7</ext-link></comment> .<?supplied-pmid 20096450?><pub-id pub-id-type="pmid">20096450</pub-id></mixed-citation></ref><ref id="pone.0197504.ref011"><label>11</label><mixed-citation publication-type="journal"><name><surname>Chen</surname><given-names>MI</given-names></name>, <name><surname>Cook</surname><given-names>AR</given-names></name>, <name><surname>Lim</surname><given-names>WY</given-names></name>, <name><surname>Lin</surname><given-names>R</given-names></name>, <name><surname>Cui</surname><given-names>L</given-names></name>, <name><surname>Barr</surname><given-names>IG</given-names></name>, <etal>et al</etal>
<article-title>Factors influencing infection by pandemic influenza A(H1N1)pdm09 over three epidemic waves in Singapore</article-title>. <source>Influenza Other Respir Viruses</source>. <year>2013</year>;<volume>7</volume>(<issue>6</issue>):<fpage>1380</fpage>&#x02013;<lpage>9</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1111/irv.12129">10.1111/irv.12129</ext-link></comment> ; PubMed Central PMCID: PMCPMC4634269.<?supplied-pmid 23829633?><pub-id pub-id-type="pmid">23829633</pub-id></mixed-citation></ref><ref id="pone.0197504.ref012"><label>12</label><mixed-citation publication-type="journal"><name><surname>Tsang</surname><given-names>TK</given-names></name>, <name><surname>Fang</surname><given-names>VJ</given-names></name>, <name><surname>Perera</surname><given-names>RA</given-names></name>, <name><surname>Ip</surname><given-names>DK</given-names></name>, <name><surname>Leung</surname><given-names>GM</given-names></name>, <name><surname>Peiris</surname><given-names>JS</given-names></name>, <etal>et al</etal>
<article-title>Interpreting Seroepidemiologic Studies of Influenza in a Context of Nonbracketing Sera</article-title>. <source>Epidemiology</source>. <year>2016</year>;<volume>27</volume>(<issue>1</issue>):<fpage>152</fpage>&#x02013;<lpage>8</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1097/EDE.0000000000000408">10.1097/EDE.0000000000000408</ext-link></comment> ; PubMed Central PMCID: PMCPMC4825848.<?supplied-pmid 26427725?><pub-id pub-id-type="pmid">26427725</pub-id></mixed-citation></ref><ref id="pone.0197504.ref013"><label>13</label><mixed-citation publication-type="journal"><name><surname>Wong</surname><given-names>JY</given-names></name>, <name><surname>Kelly</surname><given-names>H</given-names></name>, <name><surname>Ip</surname><given-names>DK</given-names></name>, <name><surname>Wu</surname><given-names>JT</given-names></name>, <name><surname>Leung</surname><given-names>GM</given-names></name>, <name><surname>Cowling</surname><given-names>BJ</given-names></name>. <article-title>Case fatality risk of influenza A (H1N1pdm09): a systematic review</article-title>. <source>Epidemiology</source>. <year>2013</year>;<volume>24</volume>(<issue>6</issue>):<fpage>830</fpage>&#x02013;<lpage>41</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1097/EDE.0b013e3182a67448">10.1097/EDE.0b013e3182a67448</ext-link></comment> ; PubMed Central PMCID: PMCPMC3809029.<?supplied-pmid 24045719?><pub-id pub-id-type="pmid">24045719</pub-id></mixed-citation></ref><ref id="pone.0197504.ref014"><label>14</label><mixed-citation publication-type="journal"><name><surname>Riley</surname><given-names>S</given-names></name>, <name><surname>Kwok</surname><given-names>KO</given-names></name>, <name><surname>Wu</surname><given-names>KM</given-names></name>, <name><surname>Ning</surname><given-names>DY</given-names></name>, <name><surname>Cowling</surname><given-names>BJ</given-names></name>, <name><surname>Wu</surname><given-names>JT</given-names></name>, <etal>et al</etal>
<article-title>Epidemiological characteristics of 2009 (H1N1) pandemic influenza based on paired sera from a longitudinal community cohort study</article-title>. <source>PLoS Med</source>. <year>2011</year>;<volume>8</volume>(<issue>6</issue>):<fpage>e1000442</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1371/journal.pmed.1000442">10.1371/journal.pmed.1000442</ext-link></comment> ; PubMed Central PMCID: PMCPMC3119689.<?supplied-pmid 21713000?><pub-id pub-id-type="pmid">21713000</pub-id></mixed-citation></ref><ref id="pone.0197504.ref015"><label>15</label><mixed-citation publication-type="journal"><name><surname>Wu</surname><given-names>P</given-names></name>, <name><surname>Presanis</surname><given-names>AM</given-names></name>, <name><surname>Bond</surname><given-names>HS</given-names></name>, <name><surname>Lau</surname><given-names>EHY</given-names></name>, <name><surname>Fang</surname><given-names>VJ</given-names></name>, <name><surname>Cowling</surname><given-names>BJ</given-names></name>. <article-title>A joint analysis of influenza-associated hospitalizations and mortality in Hong Kong, 1998&#x02013;2013</article-title>. <source>Sci Rep</source>. <year>2017</year>;<volume>7</volume>(<issue>1</issue>):<fpage>929</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/s41598-017-01021-x">10.1038/s41598-017-01021-x</ext-link></comment> ; PubMed Central PMCID: PMCPMC5430505.<?supplied-pmid 28428558?><pub-id pub-id-type="pmid">28428558</pub-id></mixed-citation></ref><ref id="pone.0197504.ref016"><label>16</label><mixed-citation publication-type="journal"><name><surname>Cowling</surname><given-names>BJ</given-names></name>, <name><surname>Chan</surname><given-names>KH</given-names></name>, <name><surname>Feng</surname><given-names>S</given-names></name>, <name><surname>Chan</surname><given-names>EL</given-names></name>, <name><surname>Lo</surname><given-names>JY</given-names></name>, <name><surname>Peiris</surname><given-names>JS</given-names></name>, <etal>et al</etal>
<article-title>The effectiveness of influenza vaccination in preventing hospitalizations in children in Hong Kong, 2009&#x02013;2013</article-title>. <source>Vaccine</source>. <year>2014</year>;<volume>32</volume>(<issue>41</issue>):<fpage>5278</fpage>&#x02013;<lpage>84</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.vaccine.2014.07.084">10.1016/j.vaccine.2014.07.084</ext-link></comment> ; PubMed Central PMCID: PMCPMC4165553.<?supplied-pmid 25092636?><pub-id pub-id-type="pmid">25092636</pub-id></mixed-citation></ref><ref id="pone.0197504.ref017"><label>17</label><mixed-citation publication-type="journal"><name><surname>Kwok</surname><given-names>KO</given-names></name>, <name><surname>Cowling</surname><given-names>B</given-names></name>, <name><surname>Wei</surname><given-names>V</given-names></name>, <name><surname>Riley</surname><given-names>S</given-names></name>, <name><surname>Read</surname><given-names>JM</given-names></name>. <article-title>Temporal variation of human encounters and the number of locations in which they occur: a longitudinal study of Hong Kong residents</article-title>. <source>J R Soc Interface</source>. <year>2018</year>;<volume>15</volume>(<issue>138</issue>). Epub 2018/01/26. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1098/rsif.2017.0838">10.1098/rsif.2017.0838</ext-link></comment> ; PubMed Central PMCID: PMCPMC5805989.<?supplied-pmid 29367241?><pub-id pub-id-type="pmid">29367241</pub-id></mixed-citation></ref><ref id="pone.0197504.ref018"><label>18</label><mixed-citation publication-type="journal"><name><surname>Kwok</surname><given-names>KO</given-names></name>, <name><surname>Cowling</surname><given-names>BJ</given-names></name>, <name><surname>Wei</surname><given-names>VW</given-names></name>, <name><surname>Wu</surname><given-names>KM</given-names></name>, <name><surname>Read</surname><given-names>JM</given-names></name>, <name><surname>Lessler</surname><given-names>J</given-names></name>, <etal>et al</etal>
<article-title>Social contacts and the locations in which they occur as risk factors for influenza infection</article-title>. <source>Proc Biol Sci</source>. <year>2014</year>;<volume>281</volume>(<issue>1789</issue>):<fpage>20140709</fpage> Epub 2014/07/11. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1098/rspb.2014.0709">10.1098/rspb.2014.0709</ext-link></comment> ; PubMed Central PMCID: PMCPMC4100506.<?supplied-pmid 25009062?><pub-id pub-id-type="pmid">25009062</pub-id></mixed-citation></ref><ref id="pone.0197504.ref019"><label>19</label><mixed-citation publication-type="journal"><name><surname>Lau</surname><given-names>JT</given-names></name>, <name><surname>Kim</surname><given-names>JH</given-names></name>, <name><surname>Choi</surname><given-names>KC</given-names></name>, <name><surname>Tsui</surname><given-names>HY</given-names></name>, <name><surname>Yang</surname><given-names>X</given-names></name>. <article-title>Changes in prevalence of influenza vaccination and strength of association of factors predicting influenza vaccination over time&#x02014;results of two population-based surveys</article-title>. <source>Vaccine</source>. <year>2007</year>;<volume>25</volume>(<issue>49</issue>):<fpage>8279</fpage>&#x02013;<lpage>89</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.vaccine.2007.09.047">10.1016/j.vaccine.2007.09.047</ext-link></comment> .<?supplied-pmid 17964010?><pub-id pub-id-type="pmid">17964010</pub-id></mixed-citation></ref><ref id="pone.0197504.ref020"><label>20</label><mixed-citation publication-type="journal"><name><surname>Chor</surname><given-names>JS</given-names></name>, <name><surname>Ngai</surname><given-names>KL</given-names></name>, <name><surname>Goggins</surname><given-names>WB</given-names></name>, <name><surname>Wong</surname><given-names>MC</given-names></name>, <name><surname>Wong</surname><given-names>SY</given-names></name>, <name><surname>Lee</surname><given-names>N</given-names></name>, <etal>et al</etal>
<article-title>Willingness of Hong Kong healthcare workers to accept pre-pandemic influenza vaccination at different WHO alert levels: two questionnaire surveys</article-title>. <source>BMJ</source>. <year>2009</year>;<volume>339</volume>:<fpage>b3391</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1136/bmj.b3391">10.1136/bmj.b3391</ext-link></comment> ; PubMed Central PMCID: PMCPMC2731837.<?supplied-pmid 19706937?><pub-id pub-id-type="pmid">19706937</pub-id></mixed-citation></ref><ref id="pone.0197504.ref021"><label>21</label><mixed-citation publication-type="journal"><name><surname>Bedford</surname><given-names>T</given-names></name>, <name><surname>Riley</surname><given-names>S</given-names></name>, <name><surname>Barr</surname><given-names>IG</given-names></name>, <name><surname>Broor</surname><given-names>S</given-names></name>, <name><surname>Chadha</surname><given-names>M</given-names></name>, <name><surname>Cox</surname><given-names>NJ</given-names></name>, <etal>et al</etal>
<article-title>Global circulation patterns of seasonal influenza viruses vary with antigenic drift</article-title>. <source>Nature</source>. <year>2015</year>;<volume>523</volume>(<issue>7559</issue>):<fpage>217</fpage>&#x02013;<lpage>20</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/nature14460">10.1038/nature14460</ext-link></comment> ; PubMed Central PMCID: PMCPMC4499780.<?supplied-pmid 26053121?><pub-id pub-id-type="pmid">26053121</pub-id></mixed-citation></ref><ref id="pone.0197504.ref022"><label>22</label><mixed-citation publication-type="journal"><name><surname>Hobson</surname><given-names>D</given-names></name>, <name><surname>Curry</surname><given-names>RL</given-names></name>, <name><surname>Beare</surname><given-names>AS</given-names></name>, <name><surname>Ward-Gardner</surname><given-names>A</given-names></name>. <article-title>The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses</article-title>. <source>J Hyg (Lond)</source>. <year>1972</year>;<volume>70</volume>(<issue>4</issue>):<fpage>767</fpage>&#x02013;<lpage>77</lpage>. ; PubMed Central PMCID: PMCPMC2130285.<?supplied-pmid 4509641?><pub-id pub-id-type="pmid">4509641</pub-id></mixed-citation></ref><ref id="pone.0197504.ref023"><label>23</label><mixed-citation publication-type="journal"><name><surname>Ng</surname><given-names>S</given-names></name>, <name><surname>Fang</surname><given-names>VJ</given-names></name>, <name><surname>Ip</surname><given-names>DK</given-names></name>, <name><surname>Chan</surname><given-names>KH</given-names></name>, <name><surname>Leung</surname><given-names>GM</given-names></name>, <name><surname>Peiris</surname><given-names>JS</given-names></name>, <etal>et al</etal>
<article-title>Estimation of the association between antibody titers and protection against confirmed influenza virus infection in children</article-title>. <source>J Infect Dis</source>. <year>2013</year>;<volume>208</volume>(<issue>8</issue>):<fpage>1320</fpage>&#x02013;<lpage>4</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1093/infdis/jit372">10.1093/infdis/jit372</ext-link></comment> ; PubMed Central PMCID: PMCPMC3778972.<?supplied-pmid 23908481?><pub-id pub-id-type="pmid">23908481</pub-id></mixed-citation></ref><ref id="pone.0197504.ref024"><label>24</label><mixed-citation publication-type="journal"><name><surname>Tsang</surname><given-names>TK</given-names></name>, <name><surname>Cauchemez</surname><given-names>S</given-names></name>, <name><surname>Perera</surname><given-names>RA</given-names></name>, <name><surname>Freeman</surname><given-names>G</given-names></name>, <name><surname>Fang</surname><given-names>VJ</given-names></name>, <name><surname>Ip</surname><given-names>DK</given-names></name>, <etal>et al</etal>
<article-title>Association between antibody titers and protection against influenza virus infection within households</article-title>. <source>J Infect Dis</source>. <year>2014</year>;<volume>210</volume>(<issue>5</issue>):<fpage>684</fpage>&#x02013;<lpage>92</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1093/infdis/jiu186">10.1093/infdis/jiu186</ext-link></comment> ; PubMed Central PMCID: PMCPMC4148604.<?supplied-pmid 24676208?><pub-id pub-id-type="pmid">24676208</pub-id></mixed-citation></ref><ref id="pone.0197504.ref025"><label>25</label><mixed-citation publication-type="journal"><name><surname>Zhao</surname><given-names>X</given-names></name>, <name><surname>Fang</surname><given-names>VJ</given-names></name>, <name><surname>Ohmit</surname><given-names>SE</given-names></name>, <name><surname>Monto</surname><given-names>AS</given-names></name>, <name><surname>Cook</surname><given-names>AR</given-names></name>, <name><surname>Cowling</surname><given-names>BJ</given-names></name>. <article-title>Quantifying Protection Against Influenza Virus Infection Measured by Hemagglutination-inhibition Assays in Vaccine Trials</article-title>. <source>Epidemiology</source>. <year>2016</year>;<volume>27</volume>(<issue>1</issue>):<fpage>143</fpage>&#x02013;<lpage>51</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1097/EDE.0000000000000402">10.1097/EDE.0000000000000402</ext-link></comment> ; PubMed Central PMCID: PMCPMC4658669.<?supplied-pmid 26427723?><pub-id pub-id-type="pmid">26427723</pub-id></mixed-citation></ref><ref id="pone.0197504.ref026"><label>26</label><mixed-citation publication-type="journal"><name><surname>Freeman</surname><given-names>G</given-names></name>, <name><surname>Perera</surname><given-names>RA</given-names></name>, <name><surname>Ngan</surname><given-names>E</given-names></name>, <name><surname>Fang</surname><given-names>VJ</given-names></name>, <name><surname>Cauchemez</surname><given-names>S</given-names></name>, <name><surname>Ip</surname><given-names>DK</given-names></name>, <etal>et al</etal>
<article-title>Quantifying homologous and heterologous antibody titre rises after influenza virus infection</article-title>. <source>Epidemiol Infect</source>. <year>2016</year>;<volume>144</volume>(<issue>11</issue>):<fpage>2306</fpage>&#x02013;<lpage>16</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1017/S0950268816000583">10.1017/S0950268816000583</ext-link></comment> .<?supplied-pmid 27018720?><pub-id pub-id-type="pmid">27018720</pub-id></mixed-citation></ref><ref id="pone.0197504.ref027"><label>27</label><mixed-citation publication-type="journal"><name><surname>Cauchemez</surname><given-names>S</given-names></name>, <name><surname>Horby</surname><given-names>P</given-names></name>, <name><surname>Fox</surname><given-names>A</given-names></name>, <name><surname>Mai le</surname><given-names>Q</given-names></name>, <name><surname>Thanh le</surname><given-names>T</given-names></name>, <name><surname>Thai</surname><given-names>PQ</given-names></name>, <etal>et al</etal>
<article-title>Influenza infection rates, measurement errors and the interpretation of paired serology</article-title>. <source>PLoS Pathog</source>. <year>2012</year>;<volume>8</volume>(<issue>12</issue>):<fpage>e1003061</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1371/journal.ppat.1003061">10.1371/journal.ppat.1003061</ext-link></comment> ; PubMed Central PMCID: PMCPMC3521724.<?supplied-pmid 23271967?><pub-id pub-id-type="pmid">23271967</pub-id></mixed-citation></ref></ref-list></back></article>